-
- Academic Editor
-
-
-
Background: Placenta previa-accreta constitutes an increasing
clinical problem, whose diagnosis remains challenging in obstetrics. The current
work aimed to assess whether second-trimester serum alpha-fetoprotein (AFP)
amounts are altered in pregnant women with placenta previa-accreta versus control
values. Methods: A retrospective chart review was performed for
504 pregnant women treated between 1 January 2016 and 28 February 2021. This
cohort included 105 placenta previa-accreta and 122 placenta previa control
cases, as well as 277 body mass index (BMI)-matched individuals with healthy
pregnancy. The multiple of the median (MoM) for AFP was obtained from clinical
records. Results: Markedly elevated MoM for AFP was
detected in the placenta previa-accreta group compared with the placenta previa
control and healthy pregnant control groups (both p
(1) The MoM for AFP is higher in the placenta previa accreta group.
(2) High AFP is positively associated with placenta accreta.
(3) The second-trimester biomarker AFP can be used to predict placenta accreta.